This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck Gets Priority Review for Keytruda in Third-Line SCLC
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
by Zacks Equity Research
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Incyte (INCY) Q4 Earnings Lag Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of -6.98% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains
by Zacks Equity Research
Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
by Zacks Equity Research
The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.
Zacks.com featured highlights include: Incyte, KEYW, First Majestic and Mattel
by Zacks Equity Research
Zacks.com featured highlights include: Incyte, KEYW, First Majestic and Mattel
4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains
by Zacks Equity Research
Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs
by Zacks Equity Research
A low key week for the biotech sector with regular drug approvals and pipeline updates.
What's in Store for Merck in 2019 After a Solid Run in '18?
by Zacks Equity Research
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Incyte (INCY) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Incyte (INCY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan
by Zacks Equity Research
Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review
by Zacks Equity Research
FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
by Zacks Equity Research
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Incyte (INCY) Collaborates with Innovent for 3 Candidates
by Zacks Equity Research
Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.